/w=32,quality=90,fit=scale-down){kind=small}
Raphael Thys
Pictured at NovaUCD is Gareth O’Sullivan, CEO, Empiric Logic. Image: Paul Sharp/Sharppix
NovaUCD-based start-up Empiric Logic is helping aCGT Vector bring its cellular treatments to patients faster using its privacy compatible data analytics tool.
Dublin biotech start-up Empiric Logic has partnered with Louth-based company aCGT Vector. The start-up, which is based out of NovaUCD at University College Dublin, will use its machine learning data analytics tools to help aCGT Vector bring its cellular therapies to market faster.
Empiric Logic was founded in 2018 and is an Enterprise Ireland high-potential start-up. It has developed an AI-powered bioinformatics platform which aims to simplify the exploration of human health, using genomics and other data. It can do so without compromising patients’ identifying data.
Last March, the start-up won an €85,000 grant to research data privacy in genomics.
Gareth O’Sullivan, CEO, Empiric Logic, said his company was happy to help aCGT Vector to bring its medicines “more efficiently and quickly to patients in Ireland and around the world.”
According to O’Sullivan, partnerships such as this enable Empiric Logic to further improve its ability to address varied use cases for its technology while also helping blend genomics analysis with analysis of other clinical and phenotype data.
“Access to well curated and quality data sources is a key driver in allowing us to help companies such as aCGT Vector improve patient outcomes,” he concluded.
aCGT Vector is a member of the Healed Consortium, which last year secured Disruptive Technologies Innovation Fund (DTIF) funding of €6.8m as part of a three-year €10.5m programme to develop next generation cell therapies for cancer. The group has rolled out cancer centres of excellence across Europe, with the first based in St James’s Hospital in Dublin. The facility opened in 2021.
aCGT Vector’s cellular therapy focus includes CAR-T (Chimeric Antigen Receptor-T) cell immunotherapy, which is rapidly evolving as a therapeutic procedural approach for the treatment of rare diseases and cancer.
Gary McAuslan, CEO, aCGT Vector, said that the company placed a “great emphasis on finding companies with an aligned vision and an eagerness to drive further innovation in precision medicine development” when looking for partners to work with.
“Empiric Logic has that vision and not only are they going to be able to help us with access to their software platform capability, they will also help us architect and further refine our data curation, collection, analysis and management process,” McAuslan added.
“This will enable us to make better use of the data we collect to support better patient care and outcomes in a secure and privacy preserving manner.”
10 things you need to know direct to your inbox every weekday. Sign up for the Daily Brief, Silicon Republic’s digest of essential sci-tech news.